medigraphic.com
ISSN 1561-3011 (Digital)

2021, Número S1

Siguiente >>

Rev Cubana Invest Bioméd 2021; 40 (S1)


Nimotuzumab combinado con quimioradioterapia en pacientes con carcinoma epidermoide esofágico avanzado en el mundo real

Lima PM, Soriano GJL, López DL, Fleites CV, Domínguez ÁC, González MM, Ortíz RJ, Morales MD, Hernández CJL, Ramón CI, Batista AN

Idioma: Español
Referencias bibliográficas: 38
Paginas: 1-26
Archivo PDF: 622.95 Kb.


RESUMEN

Introducción: La supervivencia global de pacientes con cáncer de esófago continúa siendo baja a pesar de los avances terapéuticos realizados en las últimas décadas.
Objetivo: Evaluar respuesta al tratamiento y supervivencia global.
Métodos: Se realizó un estudio retrospectivo y observacional en pacientes con carcinoma epidermoide esofágico avanzado, tratados con nimotuzumab combinado con quimioradioterapia, atendidos en el Servicio de Oncología Clínica del Hospital Ameijeiras, entre enero 2013 y junio de 2019 (n = 94). Se utilizó chi-cuadrado para la asociación de variables, con un valor p< 0,05. Se evaluó supervivencia global por el método de Kaplan Meier, y la prueba de Log-Rank para la comparación de las curvas.
Resultados: La tasa de respuesta objetiva y de control de enfermedad fue 64,9 % y 83 %, respectivamente. El esquema de quimioterapia con cisplatino/fluouracilo fue el empleado con más frecuencia. Las variables con mayor respuesta y significación estadística fueron: ECOG cero, color de piel no blanca, tratamiento radiante ≥ 50 Gy, y más de catorce dosis de nimotuzumab. La mediana de supervivencia fue 13,03 meses (IC95 % -10,9; 15,2), y las variables asociadas a una mayor probabilidad de supervivencia fueron: ECOG cero, dosis de quimioterapia > 75 % de lo planificado, tratamiento radiante ≥ 50 Gy, más de catorce dosis de nimotuzumab, y alcanzar una respuesta objetiva (p< 0,05). Solo 5,8 % de los pacientes presentaron toxicidades clasificadas como grado 3-5.
Conclusiones: En condiciones de práctica clínica, este esquema de combinación obtuvo óptimas tasas de respuesta objetiva y supervivencia con buen perfil de toxicidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. DOI: https://doi.org/10.3322/caac.21492

  2. Ministerio de Salud Pública. Anuario Estadístico de Cuba 2019. MINSAP, Dirección Nacional de Registros Médicos y Estadísticas de Salud: La Habana. 2020 [acceso 30/08/2020]. Disponible en: Disponible en: https://files.sld.cu/bvscuba/files/2020/05/AnuarioElectrónico-Español-2019-ed-2020.pdf 2.

  3. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017; 390:2383-96. DOI: https://doi.org/10.1016/S0140-6736(17)31462-9

  4. He Y, Li D, Shan B, Liang D, Shi J, Chen W, et al. Incidence and mortality of esophagus cancer in China, 2008-2012. Chin J Cancer Res. 2019;31:426-34. DOI: https://doi.org/10.21147/j.issn.1000-9604.2019.03.04

  5. Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, Brigham Women's H, Broad I, Brown U, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169-75. DOI: https://doi.org/10.1038/nature20805

  6. Yang J, Liu X, Cao S, Dong X, Rao S, Cai K. Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade. Front Oncol. 2020;10:1727. DOI: https://doi.org/10.3389/fonc.2020.01727

  7. He Y, Li D, Shan B, Liang D, Shi J, Chen W, et al. Incidence and mortality of esophagus cancer in China, 2008-2012. Chin J Cancer Res. 2019;31:426-34. DOI: https://doi.org/10.21147/j.issn.1000-9604.2019.03.04

  8. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118(5):1173-80. DOI: https://doi.org/10.1002/ijc.21454

  9. Subramanian S, Sridharan N, Balasundaram V, Chaudhari S. Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence. South Asian J Cancer. 2019;8(2):112-5. DOI: https://doi.org/10.4103/sajc.sajc_89_18

  10. Lai X, Gu Q, Zheng X, Liu G, Feng W, Lin X, Mao W. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study. J Cancer Res Ther. 2016;12(Supplement):89-95. DOI: https://doi.org/10.4103/0973-1482.191612

  11. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther. 2012;13(8):600-5. DOI: https://doi.org/10.4161/cbt.19849

  12. Lima M, Soriano JL, Martín M, Peraza C, Rodríguez M, Domínguez C, et al. Cáncer de esófago. En: Manual de Prácticas Médicas IVEdición. Unidad Funcional de Tumores. Tomo 1. La Habana: Editorial de Ciencias Médicas; 2012. p. 244-263. ISBN: 978-959-212-791-3.

  13. Brierley JD, Gospodarowicz MK, Wittekind C. (eds). TNM Classification of Malignant Tumours, 8th ed. Oxford: John Wiley & Sons, Inc.; 2016.

  14. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132-7. DOI: https://doi.org/10.1016/j.ejca.2016.03.081

  15. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Washington: 27, November 2017. [acceso 15/07/2020]. Disponible en: Disponible en: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf 15.

  16. Glasgow RE, Magid DJ, Beck A. Practical clinical trials for translating research to practice: design and measurement recommendations. Med Care. 2005;43:551-7. DOI: https://doi.org/10.1097/01.mlr.0000163645.41407.09

  17. Mahmood MQ, Shukla SD, Dua K, Shastri MD. The role of epidermal growth factor receptor in the management of gastrointestinal carcinomas: present status and future perspectives. Curr Pharm Des. 2017;23:2314-20. DOI: https://doi.org/10.2174/1381612823666170124115159

  18. Li A, Huang X, Song Y, Chen X, Sun J, Xu H, et al. Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis. Growth Factors. 2015;33(2):113-27. DOI: https://doi.org/10.3109/08977194.2015.1010643

  19. Yang YM, Hong P, Xu WW, He QY, Li B. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020;5(1):229. DOI: https://doi.org/10.1038/s41392-020-00323-3

  20. Rice TW, Apperson-Hansen C, DiPaola LM, Semple ME, Lerut TE, Orringer MB, et al. Worldwide esophageal cancer collaboration: clinical staging data. Dis Esophagus. 2016;29(7):707-14. DOI: https://doi.org/10.1111/dote.12493

  21. Hull R, Mbele M, Makhafola T, Hicks C, Wang SM, Reis RM, et al. A multinational review: Oesophageal cancer in low to middle-income countries. Oncol Lett. 2020;20(4):42. DOI: https://doi.org/10.3892/ol.2020.11902

  22. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383-96. DOI: https://doi.org/10.1016/S0140-6736(17)31462-9

  23. Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305-14. DOI: https://doi.org/10.1016/S1470-2045(14)70028-2

  24. Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v50-v57. DOI: https://doi.org/10.1093/annonc/mdw329

  25. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer. Ann Oncol. 2019;30:34-43. DOI: https://doi.org/10.1093/annonc/mdy498

  26. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin- 5 fluorouracil versus cisplatin- 5 fluorouracil alone in first - line metaststic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20(10):1667-73. DOI: https://doi.org/10.1093/annonc/mdp069

  27. Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008;70:391-5. DOI: https://doi.org/10.1016/j.ijrobp.2007.07.2325

  28. Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: The NRG Oncology RTOG 0436 Phase 3 randomized clinical trial. JAMA Oncol. 2017;3(11):1520-8. DOI: https://doi.org/10.1001/jamaoncol.2017.1598

  29. Huang ZH, Ma XW, Zhang J, Li X, Lai NL, Zhang SX. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials. BMC Cancer. 2018;18(1):1170. DOI: https://doi.org/10.1186/s12885-018-5040-z

  30. Berger C, Krengel U, Stang E, Moreno E, Madshus IH. Nimotuzumab and cetuximab block ligand independent EGF receptor signaling efficiently at different concentrations. J Immunother. 2011;34:550-5. DOI: https://doi.org/10.1097/CJI.0b013e31822a5ca6

  31. Jing W, Yan W, Liu Y, Li J, Yu J, Zhu H. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Biol Ther. 2019;20(8):1121-6. DOI: https://doi.org/10.1080/15384047.2019.1598760

  32. Xu S, Ramos-Suzarte M, Bai X, Xu B. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: A single institute experience. Oncotarget. 2016;7:33391-407. DOI: https://doi.org/10.18632/oncotarget.8516

  33. Saumell Y, Sanchez L, González S, Ortiz R, Medina E, Galán Y, et al. Overall survival of patients with locally advanced or metastatic esophageal squamous cell carcinoma treated with nimotuzumab in the real world. Adv Ther. 2017;34(12):2638-47. DOI: https://doi.org/10.1007/s12325-017-0631-7

  34. Lu M, Wang XC, Shen L, Jia J, Gong J, Li J, Li J, et al. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial. Cancer Sci. 2016;107:486-90. DOI: https://doi.org/10.1111/cas.12894

  35. de Castro Junior G, Segalla JG, de Azevedo SJ, Andrade CJ, Grabarz D, de Araújo Lima França B, et al. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial. Eur J Cancer. 2018;88:21-30. DOI: https://doi.org/10.1016/j.ejca.2017.10.005.

  36. Guo K, Wang WP, Jiang T, Wang JZ, Chen Z, Li Y, et al. Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer. J Thorac Dis. 2016;8(7):1753-63. DOI: https://doi.org/10.21037/jtd.2016.06.17

  37. Wang T, Yu J, Liu M, Chen Y, Zhu C, Lu L, et al. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. Drug Des Devel Ther. 2019;13:539-53. DOI: https://doi.org/10.2147/DDDT.S189514

  38. Han X, Lu N, Pan Y, Xu J. Nimotuzumab combined with chemotherapy is a promising treatment for locally advanced and metastatic esophageal cancer. Med Sci Monit. 2017;23:412-8. DOI: https://doi.org/10.12659/msm.902645




2020     |     www.medigraphic.com